ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index; 91 of the 188 sources its claims cite were checked for support.
Abstract
Sodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the frequent situation of patients failing to reach the therapeutic goals of symptom relief and serum TSH control. Thus, an expert task force was approved by the Guidelines Board of the European Thyroid Association to examine the available data and to formulate recommendations based on the available evidence and the experts’ deduction. The task force provides a body of suggestions to optimize the levothyroxine treatment in monotherapy, considering the key point in the individualization of treatment. Furthermore, the nutritional, pharmacological and pathological factors, potentially leading to the increased need for levothyroxine, are discussed, with a specific focus on the use of liquid and softgel formulations of the hormone.
Overview
CoChat Summary
TL;DR
This ETA guideline provides recommendations to optimize levothyroxine sodium monotherapy in hypothyroidism, emphasizing individualized treatment and management of adherence, nutritional, pharmacological, and pathological interferences. It highlights liquid and softgel LT4 formulations for patients at risk of tablet malabsorption or altered gastric pH.
Key findings
- Almost half of LT4-treated primary hypothyroid patients worldwide appear under- or over-treated when serum TSH is used as the marker of adequate thyroid hormone status.
- In a cited absorption study, a free T4 increment at 3 h above 5.15 pmol/L had 97% sensitivity and 80% specificity for excluding true malabsorption.
- Coffee co-administration decreased the incremental rise in serum T4 by 36% in hypothyroid patients and 29% in healthy volunteers, and decreased peak T4 by 30% and 19%, respectively, while delaying T4 maximum serum level by 38 and 43 min.
- A cited meta-analysis found that switching from tablet to liquid LT4 produced a pooled mean TSH reduction of 4.23 mU/L (95% CI 3.69–4.77); the guideline also reports increased LT4 needs in celiac disease (+49%), lactose intolerance (median ~31% higher), ulcerative colitis (26% higher in 12/13 patients), and RYGB (+27%).
Methods
- An expert task force approved by the ETA Guidelines Board examined available data and formulated recommendations based on available evidence and expert deduction; the methodology is provided as Supplementary Material.
- Recommendations are graded by strength, quality of evidence using Ø symbols, and agreement votes, mostly 8/8.
- The paper is a narrative guideline synthesis covering LT4 pharmacology, adherence, timing, food and drug interactions, comorbidities, special populations, and tablet versus liquid/softgel formulations.
Limitations
- The paper states that special-situation statements are mainly expert opinion based due to limited peer-reviewed publications; it also notes no focused RCTs in elderly patients, no controlled trials for fertility-treatment clinical outcomes, sparse RCTs comparing formulations, and no prospective studies systematically comparing liquid gel with solid formulations for clinical outcomes.
- The paper states that most formulation-comparison studies were small, short, non-comparable, and at high risk of selection and performance bias.
- Evident from the text: many recommendations are weak or based on low-quality evidence, and several authors report industry ties (speaker honoraria, speaker fees, or consulting for Merck, Abbott, Berlin-Chemie, and Institut Biochimique SA), although the guideline itself received no specific funding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
75 Valid · 3 Not valid · 67 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A case series article reported some clinical evidence of the refractoriness of hypothyroidism due to improper storage of tablet levothyroxine (27).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > Issues about the drug
What the sources say
- Supportedcites [27] Benvenga S, Papi G & Antonelli A. Refractory hypothyroidism due to improper storage of levothyroxine tablets. Front Endocrinol 2017 8 155. (10.3389/fendo.2017.00155) PMC5502408 28740481 source
The Abstract (Objective and Results) describes eight patients with refractory hypothyroidism who stored levothyroxine tablets improperly. It reports that serum TSH normalized in all cases after patients were advised to store new tablets away from heat, light, and humidity, supporting the cited case-series claim. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Doses of levothyroxine of approximately 1.3–1.5 μg/kg/day were reported to be sufficient in control subjects positively devoid of comorbidity or drug interference (49).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Minimal effective dose of LT4
What the sources say
- Supportedcites [49] Virili C, Bruno G, Santaguida MG, et al. Levothyroxine treatment and gastric juice pH in humans: the proof of concept. Endocrine 2022 77 102– 111. (10.1007/s12020-022-03056-1) 35477833 PMC9242941 source
In Patients and methods > Patients, the reference group reached target TSH on a mean levothyroxine dose of 1.27 µg/kg/day; the paper defined a requirement above 1.51 µg/kg/day as increased. The same section describes the reference group as lacking signs of malabsorption or dyspepsia, and the study excluded patients with specified illnesses or interfering drugs. Page numbers are not available in the supplied copy. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A randomized crossover trial in 201 older patients (60 years or older) did not detect any significant differences in the mean TSH levels between an hour before breakfast administration versus an hour after evening meal dosing regimen (43).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Timing of treatment with LT4
What the sources say
- Supportedcites [43] de Mello RB, Giassi K, Stahl G, et al. Evaluation of bedtime vs morning levothyroxine intake to control hypothyroidism in older patients: a pragmatic crossover randomized clinical trial. Front Med 2022 9 828762. (10.3389/fmed.2022.828762) PMC9261378 35814782 source
The Abstract (Materials and Methods) describes a randomized crossover trial of 201 participants aged at least 60, comparing levothyroxine 60 minutes before breakfast with 60 minutes after the last meal. The Results (Bedtime vs. Morning LT4 Intake) report no statistically significant difference in mean TSH between regimens (p = 0.107). (LLM, conf=0.94)
plainn = 201- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some types of foods and dietary supplements have been reported to reduce LT4 absorption, including soy, coffee, calcium, and grapefruit (14, 46) (Table 1).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > The search for a minimal effective dose > Interference with food
What the sources say
- Supportedcites [14] Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev 2019 40 118– 136. (10.1210/er.2018-00168) 30476027 source
The Nutrients and food interference section reports interference from soy and coffee; the Drugs interference at gastric level section says calcium preparations reduce T4 bioavailability. The discussion of intestinal transporters says grapefruit components can reduce oral availability, although their effect on thyroxine exposure was minimal. The claim is appropriately framed as what has been reported, rather than as an equally strong effect for every item. (LLM, conf=0.88)
- Supportedcites [46] Wiesner A, Gajewska D & Paśko P. Levothyroxine interactions with food and dietary supplements – a systematic review. Pharmaceuticals 2021 14 206. (10.3390/ph14030206) 33801406 PMC8002057 source
The Conclusions report decreased LT4 absorption with soy products, coffee, and calcium supplements. Section 2.9 reports that grapefruit juice reduced LT4 exposure in a study, although the authors considered the interaction small. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In conclusion, the co-prescription of LT4 with several interacting drugs or supplements can frequently lead to decreased LT4 bioavailability, which may often be clinically relevant (84).”
§ ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism > Thyroxine interaction with drugs and polypharmacy > Drug interaction with LT4 absorption
What the sources say
- Supportedcites [84] Liu H, Lu M, Hu J, et al. Medications and food interfering with the bioavailability of levothyroxine: a systematic review. Ther Clin Risk Manag 2023 19 503– 523. (10.2147/TCRM.S414460) 37384019 PMC10295503 source
The Introduction reports that many medications alter LT4 bioavailability and that interactions can elevate TSH despite dose increases. The Conclusion states that many medications, foods, and beverages impair LT4 bioavailability and recommends clinical measures to manage the interactions. These passages support the claim’s qualified statement about potentially clinically relevant effects. (LLM, conf=0.90)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
104 more claims · 52 with their cited sources checked
Create a free account to see all 158 claims and to verify the 3 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 8
- The quote only partly states this claim. 1
Citations
Cites
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Self-citationJonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“In contrast to the consistent results reported in the above studies, the effect of sex, menopausal status, and the presence of the type 2 deiodinase gene ( DIO2 ) Thr92Ala polymorphism have not been conclusive (68).”
Self-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Self-citationSurks, M. I., & Hollowell, J. G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1499 · Cited by 750 · cited 2×
“There is robust evidence that serum TSH levels increase slightly with age, particularly after the age of 65 – 70 years (9, 74).”
InfluentialLazarus, J., Brown, R. S., Daumerie, C., Hubalewska-Dydejczyk, A., Negro, R., & Vaidya, B. (2014) · European Thyroid Journal · doi:10.1159/000362597 · Cited by 742
Comparison of drug adherence rates among patients with seven different medical conditions
Briesacher, B. A., Andrade, S. E., Fouayzi, H., & Chan, K. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.437 · Cited by 587 · cited 1×
“Despite WHO stating that the mean adherence rate for long-lasting treatments is about 50%, hypothyroidism treatment has been reported to be one of the clinical conditions for which there is better patient compliance (30).”
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 4×
“Indeed, several studies have demonstrated that patients with decreased gastric acid secretion, owed to the use of proton pump inhibitors (PPIs), may need higher LT4 doses to achieve target TSH levels, long-term PPI administration presenting a heightened risk in these cases (47, 78).”
InfluentialSelf-citationLevothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307 · cited 2×
“Lean body mass is not the only variable to estimate the therapeutic post-thyroidectomy LT4 dose, owing to the disappearance of thyroidal contribution to circulating T3 (102).”
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Drugs that suppress TSH or cause central hypothyroidism
Haugen, B. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.08.003 · Cited by 252 · cited 1×
“It is worth noting that serum TSH concentrations may be altered by the patient ’ s demographic characteristics and comorbidities, concomitant drug use, assay interference and so on (3, 4).”
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 1×
“Among them, the most frequently reported ones are cold intolerance, depressed mood, decline in memory, fatigue and muscle weakness (7), affecting their health-related quality of life (QoL).”
Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases
Santini, F., Pinchera, A., Marsili, A., Ceccarini, G., Castagna, M. G., Valeriano, R., Giannetti, M., Taddei, D., Centoni, R., Scartabelli, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1306 · Cited by 226 · cited 1×
“Lean body mass is a major determinant of LT4 treatment (62).”
Persani, L., Brabant, G., Dattani, M., Bonomi, M., Feldt-Rasmussen, U., Fliers, E., Gruters, A., Maiter, D., Schoenmakers, N., & van Trotsenburg, A. S. P. (2018) · European Thyroid Journal · doi:10.1159/000491388 · Cited by 222
Self-citationEffect of calcium carbonate on the absorption of levothyroxine
Singh, N. (2000) · JAMA · doi:10.1001/jama.283.21.2822 · Cited by 219 · cited 1×
“On this ground, Singh et al. (53) reported that both acute and chronic ingestions of calcium carbonate can reduce the in vitro bioavailability of T4 by binding it in a dose-dependent fashion at medium pH 2.”
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216 · cited 1×
“However, in longitudinal studies, this reduction was not con fi rmed between pre-and post-thyroidectomy (104, 105).”
Timing of levothyroxine administration affects serum thyrotropin concentration
Bach-Huynh, T.-G., Nayak, B., Loh, J., Soldin, S., & Jonklaas, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0860 · Cited by 198 · cited 1×
“…dosing resulted in the highest and most variable TSH levels, while a regimen of LT4 being administered an hour before breakfast was associated with the lowest and least variable TSH; the bedtime LT4 regimen produced values and variability that was in-between the other two dosing regimens (41).”
Poppe, K., Bisschop, P., Fugazzola, L., Minziori, G., Unuane, D., & Weghofer, A. (2020) · European Thyroid Journal · doi:10.1159/000512790 · Cited by 196 · cited 1×
“…for women on LT4 replacement is that increasing the LT4 dose should be considered before commencing the stimulation in order to avoid under replacement at a very critical phase of the pregnancy, also taking into account the long time to obtaining steady state of serum T4 due to the half-life (90).”
Altered intestinal absorption of L-thyroxine caused by coffee
Benvenga, S., Bartolone, L., Pappalardo, M. A., Russo, A., Lapa, D., Giorgianni, G., Saraceno, G., & Trimarchi, F. (2008) · Thyroid · doi:10.1089/thy.2007.0222 · Cited by 191 · cited 1×
“This has been investigated with espresso and American ( fi lter) coffee, without milk, co-administered with LT4 (55).”
A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 10×
“Some exhaustive reviews on this topic contained most of this information (12, 13, 14, 42, 51, 77).”
InfluentialSelf-citationBurch, H. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1901214 · Cited by 164 · cited 1×
“…phenytoin, carbamazepine, salsalate, salicylate, furosemide, diclofenac, ethacrynic acid, and heparin, have been observed in vitro to displace T4 from the distribution proteins, changing the amount of thyroxine bound to plasma protein, while biotin may interfere with some T4 assay systems (79, 80).”
Roos, A., Linn-Rasker, S. P., van Domburg, R. T., Tijssen, J. P., & Berghout, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1714 · Cited by 150 · cited 1×
“In the elderly, LT4 treatment should start at low doses (12.5 – 25 μ g/kg/day) depending on the patient ’ s frailty and comorbidities (64).”
InfluentialLillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150 · cited 1×
“The detrimental effects of both over-and under-replacement have been reported (94, 95).”
Localization of human thyroxine absorption
HAYS, M. T. (1991) · Thyroid · doi:10.1089/thy.1991.1.241 · Cited by 138 · cited 2×
“The optimal absorption of LT4 is under fasting conditions, with 62 – 82% of the dose absorbed during the fi rst 3 h after ingestion (45).”
Thayakaran, R., Adderley, N. J., Sainsbury, C., Torlinska, B., Boelaert, K., Šumilo, D., Price, M., Thomas, G. N., Toulis, K. A., & Nirantharakumar, K. (2019) · BMJ · doi:10.1136/bmj.l4892 · Cited by 138 · cited 1×
“…from patient registries have demonstrated that the levels of serum TSH outside the reference intervals, in patients with LT4-treated hypothyroidism, are associated with adverse health outcomes, including ischemic heart disease events, cardiac dysrhythmias, fractures, and heart failure (5, 72, 73).”
Biondi, B., & Cooper, D. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1709318 · Cited by 135
Conversion of Thyroxine to Triiodothyronine in Normal Human Subjects
Sterling, K., Brenner, M. A., & Newman, E. S. (1970) · Science · doi:10.1126/science.169.3950.1099 · Cited by 131 · cited 1×
“The discovery in 1970 that the prohormone T4 is ef fi ciently enzymatically converted to T3 by endogenous deiodinases (18) in athyreotic patients resulted in a switch to T4 monotherapy during the next four decades: indeed, daily administration of the long-lived prohormone T4 (t1/2 ∼ 7 days) avoided…”
Liel, Y., Harman-Boehm, I., & Shany, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.2.8636317 · Cited by 129 · cited 2×
“A fi ber-enriched diet or fi ber supplements may cause malabsorption, as LT4 is non-speci fi cally absorbed by the fi bers (56); the latter is likely to delay gastric emptying (56), although this effect is most likely modi fi ed by the type of fi bers (soluble or insoluble), the quantity of fi bers…”
Pabla, D., Akhlaghi, F., & Zia, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.10.008 · Cited by 124 · cited 1×
“Evidence has been provided in vitro that pH variations of the medium interfere with T4 dissolution (48).”
Atypical celiac disease as cause of increased need for thyroxine: a systematic study
Virili, C., Bassotti, G., Santaguida, M. G., Iuorio, R., Del Duca, S. C., Mercuri, V., Picarelli, A., Gargiulo, P., Gargano, L., & Centanni, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1851 · Cited by 114 · cited 2×
“Celiac disease, one of the most common autoimmune disorders in patients with thyroid autoimmunity, may lead to a reduced absorptive surface due to intestinal villi damage and the increased mouth-to-cecum transit time, and the variations in intestinal juice pH, as well (110).”
Self-citationDiagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113 · cited 4×
“…absorption (such as intake interference, drug interference, and pH dependence), non-tablet LT4 formulations, i.e., liquid solution (LS) and softgel capsule (SG), have been manufactured and commercialized for clinical practice, although they are not available in every country (13, 107).”
InfluentialSelf-citationReference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers
Jonklaas, J., & Razvi, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30371-1 · Cited by 100 · cited 2×
“This issue is further complicated by the evidence that most cases of primary hypothyroidism are initially mild or subclinical and there is no consensus on when to start treatment (3, 9).”
Self-citationPseudomalabsorption of levothyroxine
Ain, K. B. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470150090036 · Cited by 100 · cited 1×
“However, in 1991, Ain et al. explored the issue of patient compliance vs malabsorption of medication in the context of persistent hypothyroidism, and these patients were found to have normal percentage of absorption of LT4 administration (31).”
Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion
Schubert, M. L. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000392 · Cited by 99 · cited 1×
“Helicobacter pylori infection and related gastritis represent the prototype of gastric juice alkalinization through bacterial urease activity and IL-1 β and TNF-α production (119), and is also a frequent cause of increased need for LT4 (47).”
Peeters, R. P. (2008) · Hormones · doi:10.14310/horm.2002.1111035 · Cited by 98
Self-citationLevothyroxine Use in the United States, 2008-2018
Brito, J. P., Ross, J. S., El Kawkgi, O. M., Maraka, S., Deng, Y., Shah, N. D., & Lipska, K. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2686 · Cited by 94 · cited 1×
“In addition, most LT4 users are treated based on a single, mildly elevated serum TSH or even when it is within the reference intervals, often in an inappropriate way (10).”
Torlontano, M., Durante, C., Torrente, I., Crocetti, U., Augello, G., Ronga, G., Montesano, T., Travascio, L., Verrienti, A., Bruno, R., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1067 · Cited by 92 · cited 1×
“…to the effect of deiodinase polymorphisms on the LT4 dose required to reach a target TSH concentration, one study showed that individuals with thyroid cancer with the DIO2-Thr92Ala polymorphism required a higher dose of LT4 in order to achieve near suppression of their serum TSH levels (69).”
Thyroid refractoriness in an athyreotic cretin fed soybean formula
Pinchera, A., MacGillivray, M. H., Crawford, J. D., & Freeman, A. G. (1965) · New England Journal of Medicine · doi:10.1056/nejm196507082730205 · Cited by 90 · cited 1×
“Soy protein and soy iso fl avones possibly interact with LT4 treatment, although the clinical signi fi cance remains uncertain at present (57, 58).”
Levothyroxine interactions with food and dietary supplements – a systematic review
Wiesner, A., Gajewska, D., & Paśko, P. (2021) · Pharmaceuticals · doi:10.3390/ph14030206 · Cited by 85 · cited 2×
“Some types of foods and dietary supplements have been reported to reduce LT4 absorption, including soy, coffee, calcium, and grapefruit (14, 46) (Table 1).”
Samuels, M. H., Kolobova, I., Niederhausen, M., Janowsky, J. S., & Schuff, K. G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02668 · Cited by 83 · cited 1×
“Altering the LT4 dose over 6 months does not lead to signi fi cant changes in the objective measures of quality of life, mood or cognition (75).”
New medications which decrease levothyroxine absorption
John-Kalarickal, J., Pearlman, G., & Carlson, H. E. (2007) · Thyroid · doi:10.1089/thy.2007.0060 · Cited by 82 · cited 1×
“Chromium picolinate supplementation, prescribed to control body weight, has been shown to decrease LT4 bioavailability by up to 17% (83).”
Fallahi, P., Ferrari, S. M., Camastra, S., Politti, U., Ruffilli, I., Vita, R., Navarra, G., Benvenga, S., & Antonelli, A. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2247-4 · Cited by 81 · cited 1×
“These patients have been shown to have an improvement of TSH values after switching from tablet to LS (131).”
Association of thyroid hormone treatment intensity with cardiovascular mortality among US veterans.
Evron, J. M., Hummel, S. L., Reyes-Gastelum, D., Haymart, M. R., Banerjee, M., & Papaleontiou, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11863 · Cited by 75
Effects of grapefruit juice on the absorption of levothyroxine
Lilja, J. J., Laitinen, K., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02433.x · Cited by 74 · cited 1×
“…of natural juices, particularly grapefruit and apple juice, may block the organic anion-transporting polypeptide (OATP) family and the monocarboxylate transporter (MCT) family or NTCP (sodium – taurocholate co-transporting polypeptide) carrying LT4 from the small intestine to the circulation (59).”
Thyroxine replacement: a clinical endocrinologist’s viewpoint
Eligar, V, Taylor, P., Okosieme, O., Leese, G., & Dayan, C. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216642255 · Cited by 72 · cited 2×
“Observational studies of LT4-treated patients with hypothyroidism have demonstrated that almost half of the patients have serum TSH levels that are either low or high, indicative of over-or under-replacement (2).”
Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine
Cellini, M., Santaguida, M. G., Gatto, I., Virili, C., Del Duca, S. C., Brusca, N., Capriello, S., Gargano, L., & Centanni, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1217 · Cited by 72 · cited 2×
“The median of levothyroxine requirement in patients with lactose intolerance has been estimated to be approximately 31% higher as compared to controls (113).”
Self-citationAMTCO Group, Neves, J. S., Castro Oliveira, S., Souteiro, P., Pedro, J., Magalhães, D., Guerreiro, V., Bettencourt-Silva, R., Costa, M. M., Cristina Santos, A., et al. (2018) · Obesity Surgery · doi:10.1007/s11695-017-2792-5 · Cited by 70 · cited 1×
“In obese patients, a weight-related increase in serum TSH is common, which is not due to glandular failure and returns to normal after weight loss (96).”
Kinetics of degradation of levothyroxine in aqueous solution and in solid state
Won, C. M. (1992) · Pharmaceutical Research · doi:10.1023/a:1018952415732 · Cited by 69
A. Irving, S., Vadiveloo, T., & Leese, G. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12559 · Cited by 69 · cited 1×
“Indeed, several studies have demonstrated that patients with decreased gastric acid secretion, owed to the use of proton pump inhibitors (PPIs), may need higher LT4 doses to achieve target TSH levels, long-term PPI administration presenting a heightened risk in these cases (47, 78).”
Cassio, A., Monti, S., Rizzello, A., Bettocchi, I., Baronio, F., D'Addabbo, G., Bal, M. O., & Balsamo, A. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.11.070 · Cited by 68 · cited 1×
“The use of LS showed a good performance in patients of this age group and some advantages with respect to the tablet preparation (132, 133).”
Thyroxine softgel capsule in patients with gastric-related T4 malabsorption
Santaguida, M. G., Virili, C., Duca, S. C. D., Cellini, M., Gatto, I., Brusca, N., De Vito, C., Gargano, L., & Centanni, M. (2015) · Endocrine · doi:10.1007/s12020-014-0476-7 · Cited by 68 · cited 1×
“Moreover, patients with potential (36) or de fi nite (128) impaired absorption of LT4 tablets have been included in other studies, acknowledging this as a source of potential selection bias.”
Self-citationChalmers, J. R., Dickson, G. T., Elks, J., & Hems, B. A. (1949) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9490003424 · Cited by 67 · cited 1×
“The pharmaceutical form of thyroxine available is the levothyroxine sodium salt pentahydrate (LTSS), introduced in 1949 (16).”
L-Thyroxine Absorption in Patients with Short Bowel
STONE, E., LEITER, L. A., LAMBERT, J. R., SILVERBERG, J. D. H., JEEJEEBHOY, K. N., & BURROW, G. N. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-1-139 · Cited by 66 · cited 1×
“A further cause of a reduction of the absorptive intestinal surface is represented by surgical procedures; indeed, a severe reduction of LT4 absorption, independent of the length of residual intestine has been described in patients with short bowel syndrome (115).”
The emergence of levothyroxine as a treatment for hypothyroidism
Hennessey, J. V. (2017) · Endocrine · doi:10.1007/s12020-016-1199-8 · Cited by 66 · cited 3×
“Switching among generics is not associated with clinically signi fi cant changes in TSH level for Brito et al. in a study encompassing some 16,000 patients (38) but not for others (28, 37, 39, 40).”
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63 · cited 1×
“Novel formulations of LT4 were made available by pharmaceutical companies aimed at overcoming these issues (15).”
Peroni, E., Vigone, M. C., Mora, S., Bassi, L. A., Pozzi, C., Passoni, A., & Weber, G. (2014) · Hormone Research in Paediatrics · doi:10.1159/000356047 · Cited by 63 · cited 1×
“The use of LS showed a good performance in patients of this age group and some advantages with respect to the tablet preparation (132, 133).”
Virili, C., Giovanella, L., Fallahi, P., Antonelli, A., Santaguida, M. G., Centanni, M., & Trimboli, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00010 · Cited by 61
Self-citationLevothyroxine therapy in elderly patients with hypothyroidism
Effraimidis, G., Watt, T., & Feldt-Rasmussen, U. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641560 · Cited by 60 · cited 2×
“Therefore, it is of utmost importance to avoid overtreatment of elderly hypothyroid patients on LT4 replacement, and probably rather keep TSH in the higher end of the reference range to protect the aged heart (9, 95).”
Self-citationAsik, M., Gunes, F., Binnetoglu, E., Eroglu, M., Bozkurt, N., Sen, H., Akbal, E., Bakar, C., Beyazit, Y., & Ukinc, K. (2014) · Endocrine · doi:10.1007/s12020-013-0065-1 · Cited by 58 · cited 2×
“Eliminating the disaccharide from the diet may improve patients ’ pharmacological thyroid homeostasis (112).”
Thyroxine and treatment of hypothyroidism: seven decades of experience
Mateo, R. C. I., & Hennessey, J. V. (2019) · Endocrine · doi:10.1007/s12020-019-02006-8 · Cited by 57 · cited 2×
“Levothyroxine sodium shows a markedly increased solubility and more reliable intestinal absorption compared to the free acid form of T4, and it is now the active pharmaceutical ingredient (API) of T4 tablets (17).”
The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets
Patel, H., Stalcup, A., Dansereau, R., & Sakr, A. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00387-9 · Cited by 55 · cited 1×
“A detailed comparative analysis of common drug excipients on stability and potency of LT4 (25) revealed the best outcome for binary mixtures with dibasic calcium phosphate combined with a basic ‘ pH modi fi er ’ (sodium carbonate, sodium bicarbonate, or magnesium oxide).”
Yaniv, D., Vainer, I., Amir, I., Robenshtok, E., Hirsch, D., Watt, T., Hilly, O., Shkedy, Y., Shpitzer, T., Bachar, G., et al. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26983 · Cited by 55
Fallahi, P., Ferrari, S. M., & Antonelli, A. (2016) · Endocrine · doi:10.1007/s12020-015-0836-y · Cited by 53
The economic impact of levothyroxine dose adjustments: the CONTROL HE study
Ernst, F. R., Barr, P., Elmor, R., Sandulli, W., Thevathasan, L., Sterman, A. B., Goldenberg, J., & Vora, K. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-016-0462-3 · Cited by 53 · cited 6×
“However, should these formulations be correctly prescribed to the target patients, these costs would be buffered by the reduction of the diagnostic workup (36) needed in patients with suboptimal pharmacological homeostasis.”
InfluentialCaron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09691-9 · Cited by 53 · cited 4×
“Reduced lean body mass, reduced T4 absorption and outer ring deiodination as well as the presence of comorbidities and the use of drugs are among them (14, 42, 51).”
InfluentialSelf-citationDi Donna, V., Santoro, M. G., de Waure, C., Ricciato, M. P., Paragliola, R. M., Pontecorvi, A., & Corsello, S. M. (2014) · Thyroid · doi:10.1089/thy.2014.0111 · Cited by 52
Levothyroxine therapy in gastric malabsorptive disorders
Virili, C., Brusca, N., Capriello, S., & Centanni, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.621616 · Cited by 52 · cited 1×
“…of LT4 as a Class III drug (relatively high solubility and low permeability compounds) by Biopharmaceutics Classi fi cation System (BCS), several other factors markedly impact on the solubility and/or stability of the active ingredient, such as excipients in its pharmaceutic formulation (23, 24).”
Self-citationHeemstra, K. A., Hoftijzer, H. C., Van Der Deure, W. M., Peeters, R. P., Fliers, E., Appelhof, B. C., Wiersinga, W. M., Corssmit, E. P. M., Visser, T. J., & Smit, J. W. A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03474.x · Cited by 51 · cited 1×
“Another larger study, in contrast, found no effect of this polymorphism on the LT4 dose required to achieve TSH suppression in thyroid cancer patients or TSH within the reference intervals in patients with autoimmune hypothyroidism (70).”
Self-citationPirola, I., Daffini, L., Gandossi, E., Lombardi, D., Formenti, A., Castellano, M., & Cappelli, C. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0082-9 · Cited by 47 · cited 1×
“In fact, several complicating issues are present in these patients, including signi fi cant interference by other drugs and the ef fi cacy of crushed or powdered LT4 tablet is debatable (134).”
The levothyroxine absorption test: a four-year experience (2015-2018) at the Mayo Clinic
Gonzales, K. M., Stan, M. N., Morris, J. C., Bernet, V., & Castro, M. R. (2019) · Thyroid · doi:10.1089/thy.2019.0256 · Cited by 46 · cited 1×
“Furthermore, a modi fi ed 6 h LT4 absorption test was carried out at the Mayo Clinic with patients receiving a weight-based dose of LT4 followed by serial measurements of TT4 and TSH (34).”
Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis
Jubiz, W., & Ramirez, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4360 · Cited by 45 · cited 2×
“It is interesting to note that vitamin C can improve LT4 absorption, presumably by providing an acidic gastric environment (50).”
Drug delivery: A process governed by species-specific lipophilicities
Mazák, K., & Noszál, B. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.05.017 · Cited by 44 · cited 1×
“Based on environmental pH, the T4 may exist in different ionization states from cationic prevailing in acid conditions to di-anionic at more basic pH (21).”
Biotin interference in assays for thyroid hormones, thyrotropin and thyroglobulin
Ylli, D., Soldin, S. J., Stolze, B., Wei, B., Nigussie, G., Nguyen, H., Mendu, D. R., Mete, M., Wu, D., Gomes-Lima, C. J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0866 · Cited by 44 · cited 1×
“…phenytoin, carbamazepine, salsalate, salicylate, furosemide, diclofenac, ethacrynic acid, and heparin, have been observed in vitro to displace T4 from the distribution proteins, changing the amount of thyroxine bound to plasma protein, while biotin may interfere with some T4 assay systems (79, 80).”
The ageing thyroid: implications for longevity and patient care
van Heemst, D. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00911-7 · Cited by 43 · cited 1×
“Several different variations of thyroid pathophysiology have been described in the elderly (92, 93).”
Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects
Azran, C., Porat, D., Fine-Shamir, N., Hanhan, N., & Dahan, A. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.01.001 · Cited by 42 · cited 2×
“Under these conditions, the main variations of gastric physiology are the reduced volume of water in the restricted stomach, thus interfering with the levothyroxine dissolution process and the higher gastric juice pH (120) (see Table 3).”
Ross, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42 · cited 4×
“There is robust evidence that serum TSH levels increase slightly with age, particularly after the age of 65 – 70 years (9, 74).”
InfluentialSeng Yue, C., Benvenga, S., Scarsi, C., Loprete, L., & Ducharme, M. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j36p5m · Cited by 41 · cited 1×
“However, it is known that chemical equivalence does not automatically correspond to bioequivalence, which is determined by pharmacokinetic tests on healthy volunteers (28) but may differ from actual bioequivalence in patients in different clinical settings (29).”
Novel thyroxine formulations: a further step toward precision medicine
Virili, C., Trimboli, P., & Centanni, M. (2019) · Endocrine · doi:10.1007/s12020-019-02049-x · Cited by 41 · cited 3×
“…absorption (such as intake interference, drug interference, and pH dependence), non-tablet LT4 formulations, i.e., liquid solution (LS) and softgel capsule (SG), have been manufactured and commercialized for clinical practice, although they are not available in every country (13, 107).”
Self-citationCastellana, M., Castellana, C., Giovanella, L., & Trimboli, P. (2020) · Endocrine · doi:10.1007/s12020-019-02185-4 · Cited by 41 · cited 2×
“The worldwide prevalence of gastrointestinal disorders associated with tablet LT4 malabsorption is very high (111).”
Self-citationLevothyroxine therapy in thyrodectomized patients
Miccoli, P., Materazzi, G., & Rossi, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.626268 · Cited by 40 · cited 2×
“Some studies proposed a scheme to predict the LT4 requirement after thyroidectomy (101).”
Chemistry of thyroxine: an historical perspective and recent progress on its synthesis
Chemburkar, S. R., Deming, K. C., & Reddy, R. E. (2010) · Tetrahedron · doi:10.1016/j.tet.2009.12.044 · Cited by 40
Levothyroxine dosing following bariatric surgery
Gadiraju, S., Lee, C. J., & Cooper, D. S. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2314-x · Cited by 39 · cited 1×
“Even in bariatric malabsorptive procedures, such as jejunum – ileal bypass, a threefold to fourfold higher requirement of LT4 has been demonstrated compared to normal adult patients (116).”
Levothyroxine absorption test to differentiate pseudomalabsorption from true malabsorption
Ghosh, S., Pramanik, S., Biswas, K., Bhattacharjee, K., Sarkar, R., Chowdhury, S., & Mukhopadhyay, P. (2020) · European Thyroid Journal · doi:10.1159/000504218 · Cited by 39 · cited 1×
“…diagnosed hypothyroid, 25 treated hypothyroid with TSH within the reference intervals, and 25 hypothyroid subjects with elevated TSH despite an adequate dose of LT4 over more than 6 months) and ten euthyroid subjects with true malabsorption were administered LT4 (10 μ g/kg or maximum 600 μ g) (33).”
Busnelli, A., Beltratti, C., Cirillo, F., Bulfoni, A., Lania, A., & Levi-Setti, P. E. (2022) · Thyroid · doi:10.1089/thy.2021.0656 · Cited by 36 · cited 1×
“This is due to a rapid increase of thyroid hormone-binding protein production that far exceeds the rate of increase in a normal pregnancy, the extent of which is also determined by the duration and intensity of ovarian stimulation (OS) (89).”
Robertson, H. M. A., Narayanaswamy, A. K. P., Pereira, O., Copland, S. A., Herriot, R., McKinlay, A. W., Bevan, J. S., & Abraham, P. (2014) · Thyroid · doi:10.1089/thy.2013.0661 · Cited by 35 · cited 2×
“Poor adherence to treatment has been considered for long time as the main cause of LT4 treatment failure (11).”
Samuels, M. H., Kolobova, I., Niederhausen, M., Purnell, J. Q., & Schuff, K. G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01203 · Cited by 35 · cited 1×
“Furthermore, adjusting the LT4 dose to manipulate serum TSH levels in and near the limits of the reference range does not have any signi fi cant effects on energy expenditure or body weight and composition (76).”
Papoian, V., Ylli, D., Felger, E. A., Wartofsky, L., & Rosen, J. E. (2019) · Thyroid · doi:10.1089/thy.2019.0251 · Cited by 35 · cited 1×
“However, total body weight is the measurement that is most used in clinical practice, with consequent higher LT4 doses relative to requirements in obese compared with non-obese patients (97).”
Concurrent milk ingestion decreases absorption of levothyroxine
Chon, D. A., Reisman, T., Weinreb, J. E., Hershman, J. M., & Leung, A. M. (2018) · Thyroid · doi:10.1089/thy.2017.0428 · Cited by 34 · cited 2×
“The effect of administration of LT4 alone or concomitantly with milk was investigated in a study recruiting ten healthy patients (54).”
Del Duca, S. C., Santaguida, M. G., Brusca, N., Gatto, I., Cellini, M., Gargano, L., Verga Falzacappa, C., Frattaroli, F. M., Virili, C., & Centanni, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0314 · Cited by 31 · cited 2×
“However, in longitudinal studies, this reduction was not con fi rmed between pre-and post-thyroidectomy (104, 105).”
Skelin, M., Lucijanić, T., Liberati-Čizmek, A.-M., Klobučar, S. M., Lucijanić, M., Jakupović, L., Bakula, M., Lončar, J. V., Marušić, S., Matić, T., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1686-1 · Cited by 31 · cited 4×
“Reduced lean body mass, reduced T4 absorption and outer ring deiodination as well as the presence of comorbidities and the use of drugs are among them (14, 42, 51).”
InfluentialSeppel, T., Rose, F., & Schlaghecke, R. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211442 · Cited by 30 · cited 1×
“(114).”
Cappelli, C., Pirola, I., Gandossi, E., Cristiano, A., Daffini, L., Agosti, B., Casella, C., & Castellano, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9043450 · Cited by 29 · cited 1×
“One RCT found a higher ef fi cacy of LS than tablet LT4 in terms of TSH control in patients ingesting LT4 concomitant with breakfast (130).”
Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review
Liu, H., Lu, M., Hu, J., Fu, G., Feng, Q., Sun, S., & Chen, C. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s414460 · Cited by 29 · cited 1×
“In conclusion, the co-prescription of LT4 with several interacting drugs or supplements can frequently lead to decreased LT4 bioavailability, which may often be clinically relevant (84).”
Brito, J. P., Deng, Y., Ross, J. S., Choi, N. H., Graham, D. J., Qiang, Y., Rantou, E., Wang, Z., Zhao, L., Shah, N. D., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0045 · Cited by 29 · cited 2×
“Switching among generics is not associated with clinically signi fi cant changes in TSH level for Brito et al. in a study encompassing some 16,000 patients (38) but not for others (28, 37, 39, 40).”
Ingestion of large amounts of papaya fruit and impaired effectiveness of levothyroxine therapy
Deiana, L., Marini, S., & Mariotti, S. (2012) · Endocrine Practice · doi:10.4158/ep11233.co · Cited by 28 · cited 1×
“Enzymes such as papain that are present in papaya possibly delay gastric emptying and decrease LT4 bioavailability (52).”
Levothyroxine dosage and the limitations of current bioequivalence standards
Hennessey, J. V. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0273 · Cited by 28
Perros, P., Nagy, E. V., Papini, E., Van Der Feltz-Cornelis, C. M., Weetman, A. P., Hay, H. A., Abad-Madroñero, J., Tallett, A. J., Bilas, M., Lakwijk, P., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0641 · Cited by 27 · cited 1×
“These complaints may be due to concomitant comorbidities, psychosocial factors and/or unrealistic expectations toward LT4 treatment (8).”
Fliers, E., Demeneix, B., Bhaseen, A., & Brix, T. H. (2018) · European Thyroid Journal · doi:10.1159/000493123 · Cited by 26 · cited 5×
“A Joint Position Statement from the European Thyroid Association (ETA) and Thyroid Federation International (TFI) af fi rmed that after a formulation change of levothyroxine, bioequivalence does not guarantee continued euthyroidism (39).”
InfluentialNandhra, G. K., Chaichanavichkij, P., Birch, M., & Scott, S. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165272 · Cited by 26
Ciprofloxacin and Rifampin have opposite effects on levothyroxine absorption
Goldberg, A. S., Tirona, R. G., Asher, L. J., Kim, R. B., & Van Uum, S. H. M. (2013) · Thyroid · doi:10.1089/thy.2013.0014 · Cited by 25 · cited 1×
“…is a quinolone antibiotic that has been reported to interfere with the intestinal transport of thyroxine, leading to decreased LT4 bioavailability, in contrast to rifampicin, an antibiotic used to treat several bacterial infections, including tuberculosis, which increases LT4 bioavailability (81).”
Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis.
Benvenga, S., Capodicasa, G., Perelli, S., Ferrari, S. M., Fallahi, P., & Antonelli, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00150 · Cited by 25 · cited 1×
“A defective bile production and secretion has been proposed as one of the mechanisms leading to increased need for LT4 in patients with liver cirrhosis (117).”
Serum thyrotropin and triiodothyronine levels in levothyroxine-treated patients
Ettleson, M. D., Prieto, W. H., Russo, P. S. T., de Sa, J., Wan, W., Laiteerapong, N., Maciel, R. M. B., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac725 · Cited by 25 · cited 1×
“This is because small changes in LT4 dose can lead to substantial variation in serum TSH levels (71).”
Risks of suboptimal and excessive thyroid hormone replacement across ages
Feldt-Rasmussen, U., Effraimidis, G., Bliddal, S., & Klose, M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02229-7 · Cited by 23 · cited 1×
“…patients are exposed to a chronic state of excess iodothyronines in the more sensitive target tissues, mainly the heart and bones (5), while undertreated patients may experience subtle and nonspeci fi c symptoms that are dif fi cult to distinguish from those in many other clinical situations (6).”
Self-citationRefractory hypothyroidism due to improper storage of levothyroxine tablets
Benvenga, S., Papi, G., & Antonelli, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00155 · Cited by 22 · cited 1×
“A case series article reported some clinical evidence of the refractoriness of hypothyroidism due to improper storage of tablet levothyroxine (27).”
Levothyroxine treatment and gastric juice pH in humans: the proof of concept
Virili, C., Bruno, G., Santaguida, M. G., Gargano, L., Stramazzo, I., De Vito, C., Cicenia, A., Scalese, G., Porowska, B., Severi, C., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03056-1 · Cited by 22 · cited 2×
“The presence of an acidic environment in the stomach enables the disaggregation and dissolution of tablet formulations to occur (49), thus enhancing LT4 absorption at the intestinal level.”
Self-citationTrimboli, P., Virili, C., Centanni, M., & Giovanella, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00118 · Cited by 21 · cited 1×
“From a methodological point of view, performance bias may very well be present in these studies (125, 126, 127).”
Self-citationUlcerative colitis as a novel cause of increased need for levothyroxine
Virili, C., Stramazzo, I., Santaguida, M. G., Bruno, G., Brusca, N., Capriello, S., Cellini, M., Severi, C., Gargano, L., & Centanni, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00233 · Cited by 20 · cited 2×
“The hypothetical mechanism for the higher requirement is the small intestine reduced transit time that often characterizes these patients (118).”
Self-citationLevothyroxine prescriptions trends may indicate a downtrend in prescribing
Jonklaas, J., & DeSale, S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820920551 · Cited by 19
Levothyroxine sodium pentahydrate tablets – formulation considerations
Kaur, N., & Suryanarayanan, R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.006 · Cited by 19 · cited 2×
“This process already occurs under realistic storage conditions, and along with light exposure and high temperatures, may contribute to the chemical decomposition of LT4 (26).”
Administration and pharmacokinetics of levothyroxine
Lipp, H.-P. (2021) · 70 Years of Levothyroxine · doi:10.1007/978-3-030-63277-9_2 · Cited by 18 · cited 1×
“…(18) in athyreotic patients resulted in a switch to T4 monotherapy during the next four decades: indeed, daily administration of the long-lived prohormone T4 (t1/2 ∼ 7 days) avoided post-absorptive high T3 peaks associated with unwanted side effects of the short-lived T3 (t1/2 ∼ 1 day) (19).”
Drugs and Other Substances Interfering with Thyroid Function
Montanelli, L., Benvenga, S., Hegedüs, L., Vitti, P., Latrofa, F., & Duntas, L. H. (2018) · Endocrinology · doi:10.1007/978-3-319-45013-1_27 · Cited by 18 · cited 1×
“Some exhaustive reviews on this topic contained most of this information (12, 13, 14, 42, 51, 77).”
Self-citationThe use of levothyroxine absorption tests in clinical practice
Caron, P., & Declèves, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad132 · Cited by 18 · cited 3×
“The LT4 absorption test proved to be an effective and safe way to assess refractory hypothyroidism, providing reliable information to distinguish LT4 malabsorption from ‘ pseudomalabsorption ’ , a condition of intentional or unintentional non-adherence (32).”
Is levothyroxine requirement the same for tablet and soft gel formulations?
Di Donna, V., Paragliola, R. M., de Waure, C., Papi, G., Pontecorvi, A., & Corsello, S. M. (2018) · Endocrine · doi:10.1007/s12020-017-1311-8 · Cited by 17 · cited 1×
“From a methodological point of view, performance bias may very well be present in these studies (125, 126, 127).”
The performance of levothyroxine tablet is impaired by bariatric surgery
Trimboli, P., Ossola, N., Torre, A., Mongelli, F., Quarenghi, M., Camponovo, C., Lucchini, B., Rotondi, M., Ruinelli, L., & Garofalo, F. (2022) · Endocrine · doi:10.1007/s12020-022-03289-0 · Cited by 17 · cited 1×
“%) has been described in patients who have undergone RYGB (121).”
Self-citationRazvi, S., Ryan, V., Ingoe, L. E., Pearce, S. H. S., & Wilkes, S. (2019) · European Thyroid Journal · doi:10.1159/000504047 · Cited by 16 · cited 2×
“Despite that, a more accurate (67).”
Self-citationAl-Qahtani, K. M., Aldeeri, I. A., Alshaibi, A. M., Alshabib, N. S., Barghouthi, R. M., Alyusuf, E. Y., & Jammah, A. A. (2022) · Thyroid · doi:10.1089/thy.2022.0110 · Cited by 15 · cited 1×
“No timing schedule provided advantage in maintaining thyroid control (60).”
Persiani, S., Sala, F., Manzotti, C., Colovic, M., Zangarini, M., Donazzolo, Y., Barbetta, B., Vitalini, C., Giacovelli, G., Benvenuti, C., et al. (2015) · Drug Research · doi:10.1055/s-0035-1555784 · Cited by 14 · cited 1×
“Soy protein and soy iso fl avones possibly interact with LT4 treatment, although the clinical signi fi cance remains uncertain at present (57, 58).”
In vivo dissolution of levothyroxine soft gel capsules
Fiorini, G., Ribichini, D., Pasquali, R., & Vaira, D. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1526-3 · Cited by 14 · cited 1×
“LS does not need speci fi c pathways in the gastric lumen to achieve the liberation of LT4, while SG preparation simply requires that the shell melts, which takes a few minutes (122).”
Javaid, U., Kennedy, D., Addison, C., Tsatlidis, V., & Razvi, S. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1172 · Cited by 14
Self-citationL-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · cited 2×
“Nowadays, we know that other causes may be equally relevant, as in the case of nutritional, pharmacological or pathological interferences (12, 13, 14).”
Investigating the influence of excipients on the stability of levothyroxine sodium pentahydrate
Kaur, N., & Suryanarayanan, R. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00217 · Cited by 13 · cited 1×
“…of LT4 as a Class III drug (relatively high solubility and low permeability compounds) by Biopharmaceutics Classi fi cation System (BCS), several other factors markedly impact on the solubility and/or stability of the active ingredient, such as excipients in its pharmaceutic formulation (23, 24).”
Luongo, C., De Stefano, M. A., Ambrosio, R., Volpe, F., Porcelli, T., Golia, V., Bellevicine, C., Troncone, G., Masone, S., Damiano, V., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0472 · Cited by 11 · cited 1×
“Thus, peripheral type 2 deiodinase ef fi ciency becomes relevant in maintaining circulating iodothyronine homeostasis (103).”
The economic impact of switching from synthroid for the treatment of hypothyroidism
Khandelwal, N., Johns, B., Hepp, Z., & Castelli-Haley, J. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1443110 · Cited by 10 · cited 1×
“More speci fi cally, hypothyroid treatment that is not covered by insurance typically costs € 15 –€ 50 per month or € 180 –€ 600 per year, depending on the dosage, form, country, and brand name (35, 36, 37, 38, 39).”
Belal, M. M., Youssef, A. R., Baker, H., Elalaky, N. A., Marey, A. A., Quaisy, M. A., & Rabea, E. M. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03526-z · Cited by 10 · cited 1×
“The TSH changes during Ramadan may be associated with age (inverse association), weight gain, and the number of non-adherence to LT4 days (61).”
Comparison of dosing schemes for thyroid hormone replacement therapy after thyroidectomy
Valenzuela, F., Berrios, L., Robledo, C. A., Snyder, S., Barney, J. M., Reinhart, H., & Romero Arenas, M. A. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2021.03.016 · Cited by 9 · cited 1×
“Using BMI adjustment of dose, different ways of calculating the relationship between BMI-related doses had different outcomes in relation to the achievement of euthyroidism or overdosing, respectively (98).”
de Mello, R. B., Giassi, K., Stahl, G., Machado Assis, M. L., Flores, M. S., de Lima, B. C., Piccoli, V., & da Costa Rodrigues, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.828762 · Cited by 9 · cited 1×
“A randomized crossover trial in 201 older patients (60 years or older) did not detect any signi fi cant differences in the mean TSH levels between an hour before breakfast administration versus an hour after evening meal dosing regimen (43).”
Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer
Stramazzo, I., Capriello, S., Antonelli, A., Fallahi, P., Centanni, M., & Virili, C. (2022) · HORMONES · doi:10.1007/s42000-022-00376-9 · Cited by 9 · cited 1×
“An increased dose up to 25% may be required in thyroidectomized patients to achieve the desired T4 concentration or the target TSH (105, 106).”
Self-citationKumarathunga, P. A. D. M., Kalupahana, N. S., & Antonypillai, C. N. (2021) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-21-0070 · Cited by 9 · cited 1×
“Over-the-counter protein supplements, such as whey protein, can even interfere with LT4 absorption since whey protein appears to delay the responsiveness of organic anion transporters in the ileum (82).”
Daily requirement of softgel thyroxine is independent from gastric juice pH
Virili, C., Capriello, S., Stramazzo, I., Brusca, N., Santaguida, M. G., Gargano, L., Bagaglini, M. F., Bruno, G., Severi, C., & Centanni, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002583 · Cited by 8 · cited 1×
“More speci fi cally, a recent study demonstrated in vivo that, unlike tablets, the bioavailability of softgel preparations was independent of gastric juice pH (123).”
Self-citationPeeters, R. P., & Boelen, A. (2022) · Oxford Textbook of Endocrinology and Diabetes 3e · doi:10.1093/med/9780198870197.003.0042 · Cited by 3
Self-citationAnalysis of dose-TSH response effect of levothyroxine soft-gel formulation
Trimboli, P., Piticchio, T., Dadda, Z., Stramazzo, I., Gamarra, E., Ruinelli, L., & Virili, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1340204 · Cited by 2 · cited 1×
“Not surprisingly, it has been demonstrated that athyreotic patients can be initially treated with an SG dose lower than previously stated for tablet preparation (124).”
Qian, J., & Tanni, K. A. (2021) · Endocrine · doi:10.1007/s12020-021-02833-8 · Cited by 2 · cited 4×
“The conclusion of a systematic review highlighted ‘ the limited and mixed evidence in real-world clinical and economic outcomes for generic levothyroxine ’ (37).”
Influential
Research works printed but not linked: 2
- Feldt-Rasmussen U & Klose M. Endotext [Internet]. Eds Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, et al. South Dartmouth, MA: MDText.com, Inc., 2020, 2000.
- Feldt-Rasmussen U. Laboratory measurement of thyroid-related hormones, proteins, and autoantibodies in serum. In Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text, pp 868– 907. Eds LE Braverman, DS Cooper & P Kopp. Philadelphia: Lippincott, Williams & Wilkins, 2020.
Cited by
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
Duntas, L. H., Pοlyzos, S. A., Gottwald‐Hostalek, U., Urgatz, B., & Yen, P. M. (2025) · Endocrine · doi:10.1007/s12020-025-04451-0 · Cited by 2
“Recent advancements in LT4 formulations and the use of precision dosing, patient-centered algorithms, a broader range of tablet strengths, and enhanced chemical stability support accurate dosing and maintenance of TSH-guided LT4 therapy [ 76 ].”
Self-citationPoisoning with Thyroid Hormones Used Illegally—Systematic Review
Skrzypiec‐Spring, M., Kujawa, K., Wietrzyk, A., Matuła, P., Materna, M., Michalska, W., Szumny, D., & Szeląg, A. (2025) · Pharmaceuticals · doi:10.3390/ph18121808 · Cited by 2
“According to the standard treatment for hypothyroidism, T4 is the drug [53].”
Scappaticcio, L., Martino, N. D., Ferrazzano, P., Nuzzo, M. D., Volatile, A., Caruso, P., Longo, M., Verde, M. L., Maiorino, M. I., FRANCISCIS, P. D., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.021 · Cited by 1
Self-citationWang, X., Shang, X., Li, Y. W., Lu, C., Shao, Y., Yang, D., Teng, W., & Shi, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1841255 · Cited by 5
Metadata
- Authors
- Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C.
- Affiliations
- Sapienza University of Rome (IT)
- National and Kapodistrian University of Athens (GR)
- Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital 3 , ,
- Institut für Experimentelle Endokrinologie, Charité Universitätsmedizin Berlin 4 , ,
- Erasmus MC (NL)
- Centre for Life (GB)
- Ente Ospedaliero Cantonale (CH)
- Corresponding author
- Centanni, Marco
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2025-07-07
- Volume
- 14
- Issue
- 4
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC12323320
- OpenAlex
- W4412070283
- Semantic Scholar
- 1c293e0f477cd2141c7e642a25f00dabc902f440
- Cited by
- 38
- References
- 132
- Citations by year
- 2026: 32 · 2025: 6
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- European Thyroid Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- levothyroxine, hypothyroidism, monotherapy, personalized treatment, treatment optimization, barriers to treatment adherence, dietary factors, pharmacological factors, pathological factors
- MeSH terms
- Humans, Hypothyroidism, Thyrotropin, Thyroxine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.